氟[18F]OXD-2314([18F]OXD-2314) - 药物靶点：TAU_在研适应症：Tau蛋白病，阿尔茨海默症_专利_临床

概要

基本信息

药物类型

小分子化药、诊断用放射药物

别名-

靶点

TAU

作用机制

TAU调节剂(微管相关蛋白tau调节剂)

治疗领域

神经系统疾病

在研适应症

Tau蛋白病阿尔茨海默症

非在研适应症-

原研机构

Cbd Solutions AB

在研机构

Cbd Solutions AB

Centre for Addiction & Mental Health

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与氟[18F]OXD-2314 相关的临床结果

登录后查看更多信息

100 项与氟[18F]OXD-2314 相关的转化医学

登录后查看更多信息

100 项与氟[18F]OXD-2314 相关的专利（医药）

登录后查看更多信息

1

项与氟[18F]OXD-2314 相关的文献（医药）

Nature Communications

Ligand-based design of [18F]OXD-2314 for PET imaging in non-Alzheimer’s disease tauopathies

Article

作者: Vasdev, Neil ; Murrell, Emily ; Tong, Junchao ; Lopresti, Brian J ; Mathis, Chester A ; Sandell, Johan ; Viklund, Jenny ; Ström, Peter ; Svensson, Samuel ; Lindberg, Anton ; Mason, N Scott ; Sohn, Daniel ; Stehouwer, Jeffrey S

AbstractPositron emission tomography (PET) imaging of tau aggregation in Alzheimer’s disease (AD) is helping to map and quantify the in vivo progression of AD pathology. To date, no high-affinity tau-PET radiopharmaceutical has been optimized for imaging non-AD tauopathies. Here we show the properties of analogues of a first-in-class 4R-tau lead, [18F]OXD-2115, using ligand-based design. Over 150 analogues of OXD-2115 were synthesized and screened in post-mortem brain tissue for tau affinity against [3H]OXD-2115, and in silico models were used to predict brain uptake. [18F]OXD-2314 was identified as a selective, high-affinity non-AD tau PET radiotracer with favorable brain uptake, dosimetry, and radiometabolite profiles in rats and non-human primate and is being translated for first-in-human PET studies.

100 项与氟[18F]OXD-2314 相关的药物交易

登录后查看更多信息